Marsha Roach

PhoenixSongs Biologicals

New Hepatic Co-Culture Model Offers Scientists More Predictive Drug Toxicity Data

The number one reason that drugs fail in late phase clinical trials is hepatotoxicity. This suggests that data produced at the preclinical stage was not predictive. Scientists at PheonixSongs Biologicals have developed an innovative cell culture model that they hope will take a step towards solving this issue. Marsha Roach, Executive Vice President of PheonixSongs Biologicals, tells The Scientists’ Channel about the company’s revolutionary new solution for scientists working with hepatocytes and how her team successfully cultures different cells from multiple human tissues.



LIKE 5
Marsha Roach
Health Sciences

Marsha Roach

Biography

Marsha Roach, MSc, is Executive Vice President of PhoenixSongs Biologicals. More
Follow Marsha

Marsha Roach

PhoenixSongs Biologicals

Co-founder of PhoenixSongs, Marsha Roach leads a scientific team to develop stem cell-derived cellular model by isolating stem/progenitor cells from multiple human tissues, including but not limited to liver, biliary tree, brain, umbilical cord, and then differentiating them into functionally mature cell types for research and drug discovery. Ms. Roach manages external partnerships with many of the leading pharmaceutical companies, Contract Research Organizations, other biotech companies and academic collaborators to develop these stem cell-derived model systems and validate function compared to gold standard assays.